Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLNO - US8342033094 - Common Stock

45.5 USD
+1.11 (+2.5%)
Last: 1/8/2026, 8:06:44 PM
45.8 USD
+0.3 (+0.66%)
Pre-Market: 1/9/2026, 7:00:07 AM
Fundamental Rating

3

SLNO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. SLNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. SLNO is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SLNO had negative earnings in the past year.
In the past year SLNO has reported a negative cash flow from operations.
In the past 5 years SLNO always reported negative net income.
In the past 5 years SLNO always reported negative operating cash flow.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -13.08%, SLNO belongs to the top of the industry, outperforming 81.89% of the companies in the same industry.
Looking at the Return On Equity, with a value of -15.85%, SLNO belongs to the top of the industry, outperforming 85.28% of the companies in the same industry.
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SLNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

SLNO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SLNO has been increased compared to 5 years ago.
The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SLNO has an Altman-Z score of 13.52. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 13.52, SLNO belongs to the top of the industry, outperforming 85.85% of the companies in the same industry.
A Debt/Equity ratio of 0.10 indicates that SLNO is not too dependend on debt financing.
SLNO has a Debt to Equity ratio of 0.10. This is in the lower half of the industry: SLNO underperforms 62.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z 13.52
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 16.08 indicates that SLNO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.08, SLNO belongs to the best of the industry, outperforming 92.83% of the companies in the same industry.
SLNO has a Quick Ratio of 15.88. This indicates that SLNO is financially healthy and has no problem in meeting its short term obligations.
SLNO has a better Quick ratio (15.88) than 92.83% of its industry peers.
Industry RankSector Rank
Current Ratio 16.08
Quick Ratio 15.88
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

SLNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.58%, which is quite impressive.
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 53.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y98.4%
EPS Next 2Y70.29%
EPS Next 3Y53.58%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 200M 400M 600M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

SLNO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
SLNO is valuated reasonably with a Price/Forward Earnings ratio of 11.87.
Based on the Price/Forward Earnings ratio, SLNO is valued cheaply inside the industry as 97.55% of the companies are valued more expensively.
SLNO's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.70.
Industry RankSector Rank
PE N/A
Fwd PE 11.87
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

SLNO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
SLNO's earnings are expected to grow with 53.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y70.29%
EPS Next 3Y53.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLNO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (1/8/2026, 8:06:44 PM)

Premarket: 45.8 +0.3 (+0.66%)

45.5

+1.11 (+2.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners124.99%
Inst Owner Change0%
Ins Owners1.26%
Ins Owner Change-2.9%
Market Cap2.44B
Revenue(TTM)98.67M
Net Income(TTM)-78.45M
Analysts86.32
Price Target115.81 (154.53%)
Short Float %17.56%
Short Ratio5.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)419.9%
Min EPS beat(2)80.77%
Max EPS beat(2)759.03%
EPS beat(4)2
Avg EPS beat(4)207.86%
Min EPS beat(4)-7.96%
Max EPS beat(4)759.03%
EPS beat(8)3
Avg EPS beat(8)72.02%
EPS beat(12)5
Avg EPS beat(12)44.04%
EPS beat(16)8
Avg EPS beat(16)37.6%
Revenue beat(2)2
Avg Revenue beat(2)30.96%
Min Revenue beat(2)27.34%
Max Revenue beat(2)34.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.75%
PT rev (3m)-4.37%
EPS NQ rev (1m)0.55%
EPS NQ rev (3m)175.1%
EPS NY rev (1m)50.82%
EPS NY rev (3m)91.69%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)32.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)27.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 11.87
P/S 24.77
P/FCF N/A
P/OCF N/A
P/B 4.94
P/tB 4.99
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)3.83
Fwd EY8.42%
FCF(TTM)-0.48
FCFYN/A
OCF(TTM)-0.48
OCFYN/A
SpS1.84
BVpS9.21
TBVpS9.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -13.08%
ROE -15.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.14%
Cap/Sales 0.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.08
Quick Ratio 15.88
Altman-Z 13.52
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%125.68%
EPS Next Y98.4%
EPS Next 2Y70.29%
EPS Next 3Y53.58%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year105.97%
EBIT Next 3Y70.33%
EBIT Next 5YN/A
FCF growth 1Y-9.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.95%
OCF growth 3YN/A
OCF growth 5YN/A

SOLENO THERAPEUTICS INC / SLNO FAQ

What is the ChartMill fundamental rating of SOLENO THERAPEUTICS INC (SLNO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLNO.


Can you provide the valuation status for SOLENO THERAPEUTICS INC?

ChartMill assigns a valuation rating of 4 / 10 to SOLENO THERAPEUTICS INC (SLNO). This can be considered as Fairly Valued.


How profitable is SOLENO THERAPEUTICS INC (SLNO) stock?

SOLENO THERAPEUTICS INC (SLNO) has a profitability rating of 2 / 10.


Can you provide the financial health for SLNO stock?

The financial health rating of SOLENO THERAPEUTICS INC (SLNO) is 5 / 10.